Nevi and Melanomas: Clinical Trials

1,262 trials for Nevi and Melanomas, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

599 completed, 253 terminated, 141 recruiting, 97 active not recruiting. 1262 Phase 1, 451 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11262Completed 599, Terminated 253, Recruiting 141, Active not recruiting 97, Unknown 96, Withdrawn 49, Not yet recruiting 14, Suspended 10, Enrolling by invitation 3
Phase 2451Completed 175, Terminated 91, Recruiting 75, Unknown 39, Active not recruiting 32, Withdrawn 27, Not yet recruiting 8, Suspended 3, Enrolling by invitation 1

Follow Nevi and Melanomas: new trials by email Literature Review of Nevi and Melanomas trials Research Report on Nevi and Melanomas

Trials (filtered) newest first · largest first

All 1,262 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combination Immunotherapy Targeting Melanoma
Antigen-specific CAR T, CTL and DCvac to treat melanoma. - Melanoma
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute302027-06-302026-10-30
Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases
Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2 - Uveal Melanoma, Metastatic Cutaneous Melanoma
Phase 1Not yet recruitingVastra Gotaland Region62027-01-312026-09-09
Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma
Autologous Tumor Infiltrating Lymphocytes (TIL), Melphalan, Interleukin-2 - Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma
Phase 1Not yet recruitingVastra Gotaland Region182027-01-012026-09-09
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma
Phase 1Not yet recruitingAccSalus Biosciences, Inc.402027-01-012026-10-28
Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy
Biospecimen Collection, Internet-Based Intervention, Medical Device Usage and Evaluation - Advanced Cutaneous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8
Phase 1Not yet recruitingCity of Hope Medical Center82026-12-232026-06-05
CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases
Emavusertib, Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
Phase 1 / Phase 2SuspendedMayo Clinic232026-11-302026-10-20
Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Combination Therapy With Pembrolizumab and Irinotecan in Patients With Metastatic or Recurrent Malignant Melanoma
Pembrolizumab and Irinotecan - Unresectable or Metastatic Melanoma
Phase 1 / Phase 2Not yet recruitingYonsei University462026-11-012026-09-14
Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older
Anakinra, Biospecimen Collection, Computed Tomography - Melanoma
Phase 1Not yet recruitingUniversity of Southern California402026-11-012026-09-24
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
Nivolumab and Relatlimab, Melphalan - Metastatic Melanoma, Liver Metastases
Phase 1 / Phase 2RecruitingUniversity of Wisconsin, Madison152026-11-012026-10-30
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
REGN13089-M404-M2980 - Advanced Solid Tumors
Phase 1 / Phase 2RecruitingRegeneron Pharmaceuticals3202026-10-282026-11-18
Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events
Rituximab (RTX) - Immune-Related Adverse Events
Phase 1RecruitingInge Marie Svane252026-10-152026-10-20
A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Solid Tumors
BL-M08D1 - Melanoma, Solid Tumors
Phase 1 / Phase 2RecruitingSichuan Baili Pharmaceutical Co., Ltd.302026-10-132026-10-29
Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma
RBP-01 - Uveal Melanoma
Phase 1 / Phase 2Not yet recruitingReBio Pharma302026-10-012026-08-05
Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases
DNX-2401 - Melanoma
Phase 1RecruitingM.D. Anderson Cancer Center502026-09-252026-11-02
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Bmab1700, Opdivo - Melanoma
Phase 1RecruitingBiocon Biologics UK PLC1202026-09-092026-11-06
Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC
Bexmarilimab 1mg/kg and nivolumab 1mg/kg, Bexmarilimab 3mg/kg and nivolumab 1mg/kg, Recommended Phase II Dose - Melanoma (Skin Cancer), Non Small Cell Lung Cancer
Phase 1 / Phase 2RecruitingInstitute of Cancer Research, United Kingdom622026-08-282026-09-08
A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors
SI-B037 - Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors
Phase 1RecruitingSystImmune Inc.4002026-08-242026-11-17
SL-28 for Advanced Solid Tumours
SL-28 - Head & Neck Cancer, Pancreas Carcinoma
Phase 1 / Phase 2RecruitingSecond Life Therapeutics602026-08-142026-09-15
Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma
AVT32-DRL_PB, Keytruda - Melanoma
Phase 1RecruitingAlvotech Swiss AG1202026-08-102026-08-24
SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
SI-B036 - Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors
Phase 1RecruitingSystImmune Inc.4242026-07-302026-11-04

Showing 20 of 1262. Sign in to see all of them.

Narrower conditions

Melanoma (1216)  ·  Carcinoma, Non-Small-Cell Lung (285)  ·  Carcinoma, Renal Cell (185)  ·  Neoplasm Metastasis (169)  ·  Neoplasms (168)  ·  Colorectal Neoplasms (148)  ·  Breast Neoplasms (130)  ·  Squamous Cell Carcinoma of Head and Neck (130)  ·  Ovarian Neoplasms (122)  ·  Lung Neoplasms (98)  ·  Uveal Melanoma (97)  ·  Stomach Neoplasms (93)  ·  Sarcoma (86)  ·  Pancreatic Neoplasms (81)  ·  Triple Negative Breast Neoplasms (75)

Broader conditions

Neoplasms by Histologic Type (1258)  ·  Neoplasms, Nerve Tissue (1257)  ·  Neuroectodermal Tumors (1257)  ·  Neuroendocrine Tumors (1254)  ·  Neoplasms by Site (1252)  ·  Neoplasms, Germ Cell and Embryonal (1251)  ·  Skin and Connective Tissue Diseases (1226)  ·  Skin Diseases (1225)  ·  Skin Neoplasms (1178)  ·  Neoplasms (1094)  ·  Neoplasms, Glandular and Epithelial (387)  ·  Respiratory Tract Neoplasms (348)  ·  Respiratory Tract Diseases (347)  ·  Thoracic Neoplasms (347)

Interventions

pembrolizumab (172)  ·  Nivolumab (119)  ·  Ipilimumab (107)  ·  Cyclophosphamide (87)  ·  aldesleukin (50)  ·  Interleukin-2 (49)  ·  fludarabine (43)  ·  Vemurafenib (33)  ·  Temozolomide (31)  ·  fludarabine phosphate (31)  ·  trametinib (31)  ·  dabrafenib (28)  ·  Biopsy (26)  ·  Cisplatin (20)  ·  Paclitaxel (20)

Sponsors

National Cancer Institute (NCI) (68)  ·  M.D. Anderson Cancer Center (48)  ·  Pfizer (25)  ·  Hoffmann-La Roche (20)  ·  Novartis Pharmaceuticals (20)  ·  H. Lee Moffitt Cancer Center and Research Institute (18)  ·  Memorial Sloan Kettering Cancer Center (17)  ·  Bristol-Myers Squibb (16)  ·  Mayo Clinic (16)  ·  Merck Sharp & Dohme LLC (16)  ·  Craig L Slingluff, Jr (13)  ·  Dana-Farber Cancer Institute (12)  ·  GlaxoSmithKline (11)  ·  Fred Hutchinson Cancer Center (10)  ·  Incyte Corporation (10)

Countries

United States (904)  ·  Spain (115)  ·  Australia (113)  ·  France (99)  ·  China (77)  ·  Canada (75)  ·  Germany (73)  ·  United Kingdom (72)  ·  Italy (63)  ·  Belgium (50)  ·  Netherlands (48)  ·  South Korea (41)  ·  Switzerland (39)  ·  Japan (33)  ·  Israel (31)

Top investigators

Steven A Rosenberg, M.D. (10)  ·  Steven A. Rosenberg, MD, PhD (7)  ·  F. Stephen Hodi, MD (6)  ·  Cassian Yee, MD (5)  ·  Craig L. Slingluff, Jr., MD (5)  ·  Craig L. Slingluff, MD (5)  ·  David S Schrump, M.D. (5)

Results publications

PMID 36648215, PMID 24577748, PMID 31401903, PMID 32747469, PMID 22256804, PMID 24983357, PMID 25837513, PMID 32350119, PMID 34132224, PMID 34311780, PMID 36746511, PMID 37082579, PMID 38172595, PMID 39462179, PMID 39504507, PMID 40721981, PMID 10811235, PMID 10890744, PMID 11410496, PMID 11595689, PMID 11874634, PMID 12039921, PMID 12576434, PMID 12684398, PMID 12833467, PMID 12947072, PMID 14577912, PMID 15696196, PMID 15814645, PMID 15937544, PMID 15944250, PMID 16283570, PMID 16344433, PMID 16551859, PMID 16699374, PMID 16710345, PMID 16882708, PMID 16947019, PMID 18048828, PMID 18221542, PMID 18470481, PMID 18566444, PMID 18809608, PMID 19060590, PMID 19097774, PMID 19139436, PMID 19192962, PMID 19196482, PMID 19270751, PMID 19609242

NIH funding

2023 (22), 2019 (19), 2016 (15), 2018 (12), 2015 (9), U01CA062490 (8), 2009 (7), P30CA015083 (6), P30CA072720 (6), UM1CA186709 (6), 2014 (5), 2025 (5), UM1CA186716 (5), P30CA006516 (4), P30CA016672 (4)